Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective,

Slides:

Advertisements

Similar presentations

Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer – A retrospective single institution analysis.

Advertisements

BENEFIT OF CONSOLIDATIVE RADIATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP CHEMOTHERAPY JACK PHAN, ALI MAZLOOM, L. JEFFREY.

CCO Independent Conference Highlights

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,

Large-Cell Transformation of Mycosis Fungoides Occurring at the Site of Previously Treated Cutaneous B-Cell Lymphoma Jennifer L. Herrmann, Naveed Sami

Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

The Prognostic Significance of Elevated Levels of Serum Ferritin Before Chemotherapy in Patients With Non-Hodgkin Lymphoma Kyung Ah Yoh, Ho Sup Lee,

Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management Jorge E. Cortes, Carlos.

VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study

Yuji Nakamoto Clinical Lymphoma, Myeloma and Leukemia

Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data Kathleen Lang,

Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,

An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic.

The Epidemiology and Clinical Associations of Stroke in Patients With Acute Myeloid Leukemia: A Review of 10,972 Admissions From the 2012 National Inpatient.

Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma,

Residual Cancer Lymphocytes in Patients With Chronic Lymphocytic Leukemia After Therapy Show Increased Expression of Surface Antigen CD52 Detected Using.

Epstein–Barr virus (EBV) DNA in whole blood as a superior prognostic and monitoring factor than EBV-encoded small RNA in situ hybridization in diffuse.

Prognostic Nomogram for Overall Survival in Extranodal Natural Killer/T-Cell Lymphoma Patients Kaiguo Li, Ruyue Wang, Shiting Huang, Xinbin Pan, Hongmin.

Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics Vincent T. Ma, Philip S. Boonstra,

Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care.

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma by Robert Marcus, Kevin Imrie, Andrew Belch,

Limited Utility of Surveillance Imaging for Detecting Disease Relapse in Patients With Non-Hodgkin Lymphoma in First Complete Remission Quoc Truong,

A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B- cell Non-Hodgkin Lymphoma Pallawi Torka, Priyank Patel, Wei Tan,

Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p Sandy W. Wong, Ute Hegenbart, Giovanni Palladini,

A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML Benyam Muluneh, Kaitlyn Buhlinger,

A Case of Primary Cardiac Lymphoma Showing Isolated Central Nervous System Relapse Yun Hwa Jung, In Sook Woo, Young Jae Ko, Jin Hee Lee, Jung Wook Lim,

Judy A. Trieu, Mohammad Bilal, Ali Hashmi

Subepithelial Corneal Immunoglobulin Deposition as a Manifestation of Multiple Myeloma: A Case Report and Literature Review Trent P. Wang, Steven G.

Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience AnnaLynn M. Williams, Andrea M. Baran, Carla Casulo,

Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world.

Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non–small cell lung cancer: A propensity-matched analysis Whitney S. Brandt, MD, Wanpu.

Interim Functional Imaging Is an Independent Predictor of Progression-free Survival in Advanced Classical Hodgkin Lymphoma – A Real-world Analysis Moussab.

Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France Nicolas Despiégel, Chantal Touboul, Alain.

Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study Rena Buckstein,

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell.

Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma John M. Burke,

Hemophagocytic Lymphohistiocytosis in a Patient With Multiple Myeloma

Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV- associated Non-Hodgkin's Lymphoma (AMC-075) Juan C. Ramos, Joseph A. Sparano,

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera.

Clinical Lymphoma, Myeloma and Leukemia

Clinicopathologic Analysis of POEMS Syndrome and Related Diseases

Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data Preetesh Jain, Hagop Kantarjian,

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I Carole B. Miller, Rami S. Komrokji, Ruben A. Mesa,

The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation Rohtesh S. Mehta, Antonio Di Stasi, Borje S.

A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic.

Outcomes of Mediastinoscopy and Surgery with or without Neoadjuvant Therapy in Patients with Non-small Cell Lung Cancer Who are N2 Negative on Positron.

Rituximab-Based Chemoimmunotherapy Prolongs Survival of Patients With Chronic Lymphocytic Leukemia Independently of the Time of Administration Julio.

Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single- Institution Experience Bolanle Gbadamosi, Daniel Ezekwudo, Sanjog Bastola,

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma

Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice Abdalla Awidi, Salah Abbasi,

Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review Jill A. Bell, Aaron.

Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma Stephen.

Large-Cell Transformation of Mycosis Fungoides Occurring at the Site of Previously Treated Cutaneous B-Cell Lymphoma Jennifer L. Herrmann, Naveed Sami

An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma.

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Residual Cancer Lymphocytes in Patients With Chronic Lymphocytic Leukemia After Therapy Show Increased Expression of Surface Antigen CD52 Detected Using.

Clinical Lymphoma, Myeloma and Leukemia

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Autologous Stem Cell Transplantation for POEMS Syndrome

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Presentation transcript:

Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective, Population- Based Study Øystein Fluge, Bård Mannsåker, Anders Torp, Ingvil Mjaaland, Lars Helgeland, Jan Klos, Olav Mella, Sigbjørn Berentsen, Peter Meyer Clinical Lymphoma, Myeloma and Leukemia Volume 18, Issue 2, Pages 125-135.e3 (February 2018) DOI: 10.1016/j.clml.2017.12.002 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Outline of Retrospective Study of Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Western Norway 2003 to 2008 Abbreviations: CRu = complete response unconfirmed; CSS = cancer-specific survival; HUS = Haukeland University Hospital; IPI = International Prognostic Index; LDH = lactate dehydrogenase; PD = primary progressive disease; PE = primary extranodal; PET = positron emission tomography; pts = patients; RT = radiotherapy; SUS = Stavanger University Hospital. Clinical Lymphoma, Myeloma and Leukemia 2018 18, 125-135.e3DOI: (10.1016/j.clml.2017.12.002) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Survival of Diffuse Large B-Cell Lymphoma (DLBCL) Patients, With or Without Radiotherapy (RT). The Number of Patients Included (Stages and Response Categories) Are Indicated on Each Panel. Patients With Primary Progressive Disease (PD) and Those Dying During the Chemotherapy Period Were Excluded. (A) Cancer-Specific Survival (CSS) in 211 Patients; (B) CSS in 73 Patients With Complete Response After Chemotherapy; (C) CSS in 138 Patients With Any Residual Mass After Chemotherapy; (D) Overall Survival (OS) in 138 Patients With Any Residual Mass After Chemotherapy; (E) CSS in 94 Stage II/III/IV Patients With Any Residual Mass After Chemotherapy; (F) OS in 94 Stage II/III/IV Patients With Any Residual Mass After Chemotherapy; (G) CSS in 60 Patients With a Clear Residual Mass (PR or CR Unconfirmed [CRu]) After Chemotherapy; (H) OS in 60 Patients With a Clear Residual Mass (PR or CRu) After Chemotherapy Abbreviation: pts = patients. Clinical Lymphoma, Myeloma and Leukemia 2018 18, 125-135.e3DOI: (10.1016/j.clml.2017.12.002) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Survival of Diffuse Large B-Cell Lymphoma (DLBCL) Patients, With or Without Radiotherapy (RT). The Number of Patients Included (Stages and Response Categories) Are Indicated on Each Panel. Patients With Primary Progressive Disease (PD) and Those Dying During the Chemotherapy Period Were Excluded. (A) Cancer-Specific Survival (CSS) in 211 Patients; (B) CSS in 73 Patients With Complete Response After Chemotherapy; (C) CSS in 138 Patients With Any Residual Mass After Chemotherapy; (D) Overall Survival (OS) in 138 Patients With Any Residual Mass After Chemotherapy; (E) CSS in 94 Stage II/III/IV Patients With Any Residual Mass After Chemotherapy; (F) OS in 94 Stage II/III/IV Patients With Any Residual Mass After Chemotherapy; (G) CSS in 60 Patients With a Clear Residual Mass (PR or CR Unconfirmed [CRu]) After Chemotherapy; (H) OS in 60 Patients With a Clear Residual Mass (PR or CRu) After Chemotherapy Abbreviation: pts = patients. Clinical Lymphoma, Myeloma and Leukemia 2018 18, 125-135.e3DOI: (10.1016/j.clml.2017.12.002) Copyright © 2017 The Authors Terms and Conditions